At Week 24, patients treated with TEPEZZA achieved a 2.41 mm reduction in proptosis from baseline compared with 0.92 mm for those receiving placebo 62% of patients treated with TEPEZZA had. | April 10, 2023
Announced today by Horizon Therapeutics, the positive and statistically significant data supports the efficacy of teprotumumab across a spectrum of patients with TED regardless of disease activity or duration.
Dazodalibep has successfully improved disease activity and symptoms two patient populations with Sjögren’s syndrome in a phase 2 trial, according to a press release from Horizon Therapeutics. The company added that dazodalibep (VIB4920, Horizon), a CD40 ligand antagonist, is currently the only drug in development to achieve the primary endpoint in these populations in a phase 2 trial.
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the first subject has been dosed in a Phase 1 randomized, placebo-controlled trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics